[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631377":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":52,"collaborators":55,"id":62,"slug":10,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":87,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Christian Hospital Northeast Northwest","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group",null,"This is the only group. All subjects will receive ziconotide via the Medtronic Synchromed intrathecal pump.",[13],"Drug: Ziconotide",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Ziconotide","Real world evidence trial. Patients that are on intrathecal ziconotide will be observed for two years, to determine whether or not this drug is effective for chemotherapy induced peripheral neuropathy.",[9],[21],{"name":22,"affiliation":23,"role":24},"Christopher L Beuer, MD","BJC TeamHealth","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Maksim Shoykhet, BSN","CONTACT","314-653-5228","maksim.shoykhet@bjc.org",{"name":32,"role":28,"phone":29,"phoneExt":10,"email":33},"Cassandra Wania, BSN","cassandra.wania@bjc.org",[35],{"facility":36,"status":10,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Christian Hospital","St Louis","Missouri","63136","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-90.19789,38.62727,{"lat":46,"lon":45},[49,50,51],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},{"name":32,"role":28,"phone":29,"phoneExt":10,"email":33},{"name":22,"role":24,"phone":10,"phoneExt":10,"email":10},{"type":24,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Christopher Beuer, MD","Medical Director- Pain Management\u002FPrincipal Investigator",[56,59],{"name":57,"class":58},"TerSera Therapeutics LLC","INDUSTRY",{"name":60,"class":61},"TeamHealth","UNKNOWN","100631377",false,"NCT07499882","Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy","Observational and Data Collection Study About Intrathecal Ziconotide in the Treatment of Chemotherapy Induced Neuropathy","Inclusion Criteria:\n\n* Adult patients, ages 18-100, with chemotherapy-induced peripheral neuropathy as a primary source of pain\n* The patient is already scheduled to be treated with TDD using ziconotide (no reported allergies to ziconotide or drug-drug interactions expected)\n* Patient will have, or is scheduled to have, Medtronic Synchromed Intrathecal Pump implanted by Dr. Beuer (outside of the research)\n* Patients already taking nonopioid analgesics will be allowed to continue their prescribed medication regimen.\n* Patients currently taking opioid analgesics must undergo a washout period of 2 weeks (prior to device implant) before participating in this study. Those unable to adhere to this washout period will be excluded\n\nExclusion Criteria:\n\n* Patients with other forms of neuropathy (diabetic, idiopathic) will be excluded\n* Patients with a spinal cord stimulator will be excluded\n* Patients with contraindications to intrathecal ziconotide will be excluded\n* Patients who cannot sign the consent, participate in research activities, or those who require a legally authorized representative (LAR) will be excluded\n* Patients who are pregnant and\u002For nursing or planning to become pregnant are excluded\n* Also excluded are those inaccessible for follow-up, participation is excluded by local law, or a patient is currently enrolled or plans to enroll in a concurrent drug\u002Fdevice study","ALL","18 Years","100 Years",{"count":72,"type":73},24,"ESTIMATED","OBSERVATIONAL","The purpose of this observational, data collection, research is to evaluate if ziconotide, a commercially approved medication given by a FDA cleared intrathecal pump, for chronic pain is effective in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) a common and often long-lasting side effect of cancer treatment.",[77],"Chemotherapy Induced Peripheral Neuropathy (CIPN)",[79,80,81,82,83,84,85,86],"intrathecal pump","ziconotide","chronic pain","targeted drug delivery","neuropathy","cipn","chemotherapy induced neuropathy","neuropathy after cancer treatment","NOT_YET_RECRUITING","2026-03-25",{"date":90,"type":91},"2026-03-30","ACTUAL",{"date":93,"type":73},"2026-05-02",{"date":95,"type":73},"2028-05-01",{"name":5,"class":6},1]